Sequential Therapy With JX-594, A Targeted Oncolytic Poxvirus, Followed by Sorafenib in Hepatocellular Carcinoma: Preclinical and Clinical Demonstration of Combination Efficacy

JX-594 is a targeted and granulocyte-macrophage colony stimulating factor (GM-CSF) expressing oncolytic poxvirus designed to selectively replicate in and destroy cancer cells through viral oncolysis and tumor-specific immunity. In a phase 1 trial, JX-594 injection into hepatocellular carcinoma (HCC)...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Heo, Jeong, Breitbach, Caroline J, Moon, Anne, Kim, Chang Won, Patt, Rick, Kim, Mi Kyung, Lee, Yu Kyung, Oh, Sung Yong, Woo, Hyun Young, Parato, Kelley, Rintoul, Julia, Falls, Theresa, Hickman, Theresa, Rhee, Byung-Geon, Bell, John C, Kirn, David H, Hwang, Tae-Ho
Formato: Artigo
Lenguaje:Inglês
Publicado: Nature Publishing Group 2011
Materias:
Original Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3129795/
https://ncbi.nlm.nih.gov/pubmed/21427706
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/mt.2011.39
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares